These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7138751)

  • 21. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.
    Plosker GL; Clissold SP
    Drugs; 1992 Mar; 43(3):382-414. PubMed ID: 1374320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metoprolol administered once daily in the treatment of hypertension. A double-blind crossover comparison between conventional tablets and metoprolol Durules.
    Asplund J; Ohman P
    Ann Clin Res; 1981; 13 Suppl 30():30-6. PubMed ID: 7027891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-daily deta-blockers and blood-pressure response to exercise.
    Harry JD; Cruickshank JM; Young J
    Lancet; 1979 Aug; 2(8136):250. PubMed ID: 89357
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of a week's beta-adrenoceptor blockade with atenolol and metoprolol CR/ZOK on the response to exercise in healthy women aged 50 to 70 years.
    Patrick J; Bassey J; Morrant J; Macdonald I
    J Clin Pharmacol; 1990 Feb; 30(S2):S108-16. PubMed ID: 2312773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with beta-blockers--the value of an even plasma concentration over 24 h.
    Agewall S; Kendall M
    J Clin Pharm Ther; 1997 Jun; 22(3):171-9. PubMed ID: 9447471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.
    Kendall MJ; John VA; Quarterman CP; Welling PG
    Eur J Clin Pharmacol; 1980 Feb; 17(2):87-92. PubMed ID: 7371709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.
    Floras JS; Jones JV; Hassan MO; Sleight P
    Br Med J (Clin Res Ed); 1982 Nov; 285(6352):1387-92. PubMed ID: 6814568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses.
    Lücker P; Moore G; Wieselgren I; Olofsson B; Bergstrand R
    J Clin Pharmacol; 1990 Feb; 30(S2):S17-27. PubMed ID: 2312775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability in the pharmacokinetics of atenolol and metoprolol.
    Ledermann H; Bippi H; Boekens H; Frölich JC; Herrmann H; Schmitt-Landherr K
    Arzneimittelforschung; 1985; 35(5):848-51. PubMed ID: 4026908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multiple dose pharmacokinetic and pharmacodynamic evaluation of conventional and 19/285 Oros formulations of metoprolol in healthy volunteers.
    Grainger SL; John VA; Shotton PA; Smith SE
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):239S-244S. PubMed ID: 4005129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary effects of long-term beta 2-blockade in healthy subjects: comparative study of metoprolol OROS.
    Bauer K; Rakusan S; Kaik G
    Am Heart J; 1990 Aug; 120(2):473-7. PubMed ID: 1974382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic comparison of a new controlled-release formulation of metoprolol with a traditional slow-release formulation.
    Oosterhuis B; Jonkman JH; Kerkhof FA
    Eur J Clin Pharmacol; 1988; 33 Suppl():S15-8. PubMed ID: 3371389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol?
    Kendall M; Akhlaghi S; Hughes B; Lewis H
    J Clin Pharmacol; 1990 Feb; 30(S2):S98-102. PubMed ID: 2155948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of atenolol and metoprolol in the treatment of hypertension.
    Rasmussen S; Arnung K; Eskildsen PC; Nielsen PE
    Br J Clin Pharmacol; 1981 Dec; 12(6):887-91. PubMed ID: 7340890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: a comparison with atenolol.
    Fagerberg B; Berglund A; Holme E; Wilhelmsen L; Elmfeldt D
    J Intern Med; 1990 Jan; 227(1):37-43. PubMed ID: 2405089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.